Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency
2022 · Advanced Science · 610 citations
https://doi.org/10.1002/advs.202201734
K
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
348
Papers
15.3K
Citations
75
h-index
216
i10-index
Kui Luo is an academic researcher from University of Science and Technology of China. The author has contributed to research in topics: Nanoplatforms for cancer theranostics & Nanoparticle-Based Drug Delivery & RNA Interference and Gene Delivery. The author has an h-index of 75, co-authored 296 publications.
ORCID: 0000-0002-3536-1485Papers by this author
worksPreparation and application of pH-responsive drug delivery systems
2022 · Journal of Controlled Release · 504 citations
https://doi.org/10.1016/j.jconrel.2022.05.056
Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy
2017 · Acta Biomaterialia · 175 citations
https://doi.org/10.1016/j.actbio.2017.02.047
Dendrimer–doxorubicin conjugate as enzyme-sensitive and polymeric nanoscale drug delivery vehicle for ovarian cancer therapy
2014 · Polymer Chemistry · 141 citations
https://doi.org/10.1039/c4py00601a
GSH-sensitive polymeric prodrug: Synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine
2021 · Acta Pharmaceutica Sinica B · 139 citations
https://doi.org/10.1016/j.apsb.2021.05.003
Polysaccharide-based nanomedicines for cancer immunotherapy: A review
2021 · Bioactive Materials · 137 citations
https://doi.org/10.1016/j.bioactmat.2021.03.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat